Degradation of N-nitrosamines and 1,4-dioxane using vacuum ultraviolet irradiation (UV254+185 nm or UV172 nm).

Advanced oxidation processes (AOPs) play a vital role in attenuating contaminants of emerging concern (CECs) during potable water reuse. AOPs are conventionally performed by irradiating with a 254-nm low-pressure (LP) mercury-vapor (Hg) ultraviolet (UV) lamp along with chemical treatment. Compared with UV-C light treatment (200-280 nm), vacuum-UV (V-UV) light treatment (100-200 nm) is advantageous in terms of hydroxyl radical generation without the requirement for chemical treatment. This study assessed the potential of V-UV (172-nm Xe2 excimer or 185 + 254-nm LP-Hg) lamps on the destruction of two major CECs in potable water reuse, namely N-nitrosodimethylamine (NDMA) and 1,4-dioxane. Direct irradiation using UV254 nm or UV185+254 nm lamps achieved ≥94% removal of N-nitrosamines, including NDMA, at a UV dose of 900 mJ/cm2. In contrast, the Xe2 excimer lamp (UV172 nm) was less effective for N-nitrosamine removal, achieving up to 82% removal of NDMA. The removal of 1,4-dioxane by V-UV lamps at a UV dose of 900 mJ/cm2 reached 51% (UV172 nm) and 28% (UV185+254 nm), both of which results were superior to that obtained using a conventional UV254 nm lamp (10%). The addition of hydrogen peroxide during UV254 nm or UV185+254 nm irradiation was found to enhance the removal of 1,4-dioxane, while UV172 nm irradiation without hydrogen peroxide addition still exhibited greater efficiencies than those UV254 nm lamps-based AOPs. Overall, this study demonstrated that the removal of both NDMA and 1,4-dioxane can be successfully achieved using either a UV254+185 nm lamp with hydrogen peroxide or a UV172 nm Xe2 excimer lamp without hydrogen peroxide.

Treatment of 1,4-dioxane-containing water using carriers immobilized with indigenous microorganisms in landfill leachate treatment sludge: A laboratory-scale reactor study.

1,4-Dioxane (DX) is a contaminant of emerging concern in aquatic environments, and is frequently found in landfill leachate. As a biological method applicable to landfill leachate treatment facilities, the feasibility of DX treatment using carriers immobilized with microorganisms indigenous to landfill leachate treatment sludge was explored through laboratory-scale reactor experiments by introducing carriers prepared via microorganism immobilization in the aeration tank of a leachate treatment facility. Three different carrier materials were used to immobilize microorganisms, and a model DX-containing water (10 mg/L) was treated under continuous feeding. Biological DX removal to < 0.5 mg/L was achieved using all carrier types, thereby adhering to the effluent standard for landfill leachate in Japan, which confirms the usefulness of the proposed method. However, weaker aeration and enhanced DX loading drastically impaired the DX removal performance depending on the carrier materials. This suggests the importance of carrier selection and control of the operational variables to ensure stable and effective DX removal. Microbial community analyses revealed that Pseudonocardia with thm genes may largely contribute to the initial oxidation of DX, irrespective of the carrier type, suggesting the importance of this population for the continuous treatment of low DX concentrations with mixed microbial consortia.

Correction to: Surfactant protein A as a biomarker of outcomes of anti-fibrotic drug therapy in patients with idiopathic pulmonary fibrosis.

Following publication of the original article [1], the authors have flagged that there is an error in Fig. 3.

Surfactant protein A as a biomarker of outcomes of anti-fibrotic drug therapy in patients with idiopathic pulmonary fibrosis.

BACKGROUND: Idiopathic pulmonary fibrosis (IPF) is a progressive and fibrosing lung disease with poor prognosis. Pirfenidone and nintedanib are anti-fibrotic drugs used for patients with IPF. These drugs reduce the rate of decline in forced vital capacity (FVC). Serum surfactant protein (SP)-A, SP-D, and Krebs von den Lungen-6 (KL-6) are monitoring and prognostic biomarkers in patients with IPF; however, their relationship with the therapeutic outcomes of anti-fibrotic drugs has not been investigated. We aim to clarify whether serum SP-A, SP-D, and KL-6 reflect therapeutic outcomes of pirfenidone and nintedanib administration in patients with IPF. METHODS: We retrospectively investigated patients with IPF who were initiated on pirfenidone or nintedanib administration between January 2014 and June 2018 at our hospital. Changes in clinical parameters and serum SP-A, SP-D, and KL-6 levels were evaluated. Patients with ≥10% decline in FVC or ≥ 15% decline in diffusing capacity of the lung for carbon monoxide (DLco) from baseline to 6 months were classified as progression group, while the other patients were classified as stable group. RESULTS: Forty-nine patients were included (pirfenidone, 23; nintedanib, 26). Stable group comprised 32 patients, while progression group comprised 17 patients. In the stable group, changes in SP-A and KL-6 from baseline to 3 and 6 months significantly decreased compared with the progression group (SP-A: 3 months - 6.0% vs 16.7%, 6 months - 10.2% vs 20.2%, KL-6: 3 months - 9.2% vs 6.7%, 6 months - 15.0% vs 12.1%, p < 0.05). Changes in SP-A and SP-D levels showed significant negative correlations with the change in %FVC (r = - 0.46 and r = - 0.39, p < 0.01, respectively) and %DLco (r = - 0.67 and r = - 0.54, p < 0.01, respectively). Similar results were also seen in subgroup analysis for both pirfenidone and nintedanib groups. On logistic regression analysis, decrease in SP-A from baseline to 3 months and 6 months was found to predict the outcomes at 6 months (odds ratios: 0.89 and 0.88, respectively). CONCLUSIONS: Changes in serum SP-A reflected the outcomes of anti-fibrotic drug therapy. Serum SP-A has a potential as a biomarker of therapeutic outcomes of anti-fibrotic drugs.

A case of tracheal pleomorphic adenoma misdiagnosed as asthma.

A 51-year-old woman had an incidental finding of a tracheal tumor during oesophagogastroduodenoscopy following the diagnosis of asthma for 2 months. A computed tomography scan revealed a 15-mm tumor in the subglottis. Endoscopic resection was performed safely, and pleomorphic adenoma was diagnosed histologically. The patient's condition was satisfactory 30 months after the procedure. Tracheal pleomorphic adenoma is rare and may be misdiagnosed as asthma. If the tumor is large, surgery may be required; however, endoscopic polypectomy may be effective if the tumor is small. Therefore, early diagnosis of tracheal pleomorphic adenoma is important. At the first visit, the flow-volume curve suggested upper airway obstruction, which should have raised the suspicion of an upper airway obstruction. In patients with suspected asthma, early pulmonary function testing is needed to substantiate asthma diagnosis and prevent an alternative diagnosis being missed.

Autoimmune Pulmonary Alveolar Proteinosis Diagnosed after Exposure to a Fire Extinguisher Containing Silica Powder.

We herein report a case of autoimmune pulmonary alveolar proteinosis (PAP) diagnosed after one-time exposure to silica powder. Owing to the misuse of a silica-containing fire extinguisher and the inhalation of large amounts of its powder, the patient experienced prolonged cough and visited our hospital. The findings of chest computed tomography and surgical lung biopsy specimens led to the diagnosis of PAP. Interestingly, the presence of anti-GM-CSF antibody was detected; therefore, both autoimmune characteristics and exposure to large amounts of silica may have caused the development of PAP in this patient. This case provides important insight into the mechanisms leading to the onset of PAP.